OTC · NPTX
Neuropathix, Inc.
$0.00$0.00 (0.0%)
Neuropathix, Inc.: Healthcare · Biotechnology.
Loading market information…
OTC · HGENQ · USD
Stock price
Quote as of Jul 11, 2024, 06:52 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Humanigen, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies that prevent and manage an overactive immune response. At the forefront of its pipeline is lenzilumab, a monoclonal antibody designed to neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF) by binding to it. This drug has been investigated for mitigating the cytokine storm in COVID-19 patients, having successfully completed a Phase 3 trial. It is also currently being evaluated in a Phase 2/3 study supported by the NIH. Furthermore, lenzilumab's potential extends to various other conditions: it is being explored in conjunction with CD19-targeted CAR-T cell therapies and for several inflammatory disorders, including acute Graft versus Host Disease (GvHD) following allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. The company is also investigating its use in chronic myelomonocytic leukemia (CMML) for individuals with RAS pathway mutations. Beyond lenzilumab, Humanigen's pipeline features additional 'Humaneered' monoclonal antibodies. These include ifabotuzumab, which binds to EphA3, and HGEN005, designed to target EMR1. HGEN005 is under development for various eosinophilic conditions, such as eosinophilic leukemia, both as a standalone antibody and as a foundational component for innovative CAR-T constructs. Established in 2000 and based in Short Hills, New Jersey, Humanigen, Inc. recently announced a significant corporate development: on January 3, 2024, the company voluntarily filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$0.00$0.00 (0.0%)
Neuropathix, Inc.: Healthcare · Biotechnology.
$0.00-$0.01 (-98.33%)
Total Brain Limited: Healthcare · Medical - Healthcare Information Services.
$1.01$0.00 (0.0%)
Cantabio Pharmaceuticals, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
Diagnocure, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
NMC Health plc’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
$8.30-$16,591.70 (-99.95%)
QSAM Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.95% below the high.
$0.00$0.00 (0.0%)
Navidea Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.77% below the high.
$0.00$0.00 (0.0%)
Gelesis Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
